AK5 inhibitors refer to a class of chemical compounds that specifically target and inhibit the activity of adenylate kinase 5 (AK5), a member of the adenylate kinase family of enzymes. Adenylate kinases play a pivotal role in cellular energy homeostasis by catalyzing the reversible transfer of phosphate groups between adenosine triphosphate (ATP) and adenosine monophosphate (AMP) to regulate cellular nucleotide balance. AK5, in particular, is found primarily in the brain and has been shown to contribute to cellular processes related to energy metabolism, signal transduction, and metabolic stress response. Inhibition of AK5 can lead to alterations in ATP-AMP ratios and disrupt the energy balance within cells, thereby affecting various energy-dependent pathways. The intricate control of ATP levels is crucial for maintaining normal cellular function, as ATP is the primary energy currency of the cell. By inhibiting AK5, researchers are able to modulate key biochemical reactions involved in the energetics of specialized cells, particularly neurons.
Structurally, AK5 inhibitors are designed to interact with the catalytic domain of the AK5 enzyme, specifically binding to its active site and preventing its phosphate transfer activity. The active site of AK5 shares a highly conserved motif with other members of the adenylate kinase family, making the design of specific inhibitors a significant challenge due to potential cross-reactivity with other isoforms like AK1 or AK2. Chemical synthesis of these inhibitors often involves fine-tuning structural features to enhance selectivity, potency, and binding affinity for AK5 over other related kinases. Studying the molecular interactions between AK5 and its inhibitors offers valuable insights into how enzyme inhibition alters cellular biochemical pathways, making this an area of significant interest in biochemical and molecular biology research. Advanced spectroscopic and crystallographic methods are typically employed to understand how these inhibitors fit within the enzyme's active site, providing detailed information on binding modes and conformational changes upon inhibition.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Apigenin | 520-36-5 | sc-3529 sc-3529A sc-3529B sc-3529C sc-3529D sc-3529E sc-3529F | 5 mg 100 mg 1 g 5 g 25 g 100 g 1 kg | $33.00 $214.00 $734.00 $1151.00 $2348.00 $3127.00 $5208.00 | 22 | |
Inhibits CK2 kinase, which phosphorylates AK5. Reduced phosphorylation decreases AK5 activity in ATP production. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor affecting AKT phosphorylation, which in turn affects AK5's capability to sustain cellular ATP levels. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor that affects AKT, indirectly causing a decrease in AK5-mediated ADP to ATP conversion. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Broad kinase inhibitor that includes CK2, thereby reducing AK5 phosphorylation and function. | ||||||
Allopurinol | 315-30-0 | sc-207272 | 25 g | $131.00 | ||
Inhibits xanthine oxidase, reducing the availability of substrates for AK5 catalytic activity. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
c-Raf inhibitor that alters MAPK signaling. This affects ERK and subsequently modulates AK5 function. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Tyrosine kinase inhibitor that can affect AK5 by disrupting phosphorylation pathways linked to ATP production. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Inhibits CK2 and affects AK5 by reducing its phosphorylation, thereby affecting its ATP generating capability. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor affecting cellular energy metabolism, thereby indirectly reducing the need for AK5 catalytic action. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AMPK activator affecting cellular ATP needs, thus indirectly affecting AK5's role in ATP balance. | ||||||